Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 5Etoposide 4Pemetrexed 3Carboplatin 3pembrolizumab 2belinostat 2RRx-001 2vosaroxin 1taxane 1sagopilone 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1atezolizumab 1abiraterone 1Vinorelbine 1Rhenium 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1PM 01183 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1GSK2879552 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Small Cell × EC regimen × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡